/**
 * Seed script — creates SEO-optimized peptide blog posts.
 * Run with: npx tsx src/scripts/seed-blog-peptides.ts
 */
import 'dotenv/config';
import { db } from '../lib/db';
import { blogPosts } from '@pharmaflow/db/schema';

const posts = [
  // ─── POST 1 ───────────────────────────────────────────────────────────────
  {
    slug: 'tirzepatide-vs-semaglutide-which-is-better-for-weight-loss',
    title: 'Tirzepatide vs Semaglutide: Which Is Better for Weight Loss?',
    excerpt:
      'Tirzepatide and semaglutide are the two most powerful weight-loss peptides available today. We compare their mechanisms, clinical results, side effects, and which one may be right for your research goals.',
    featuredImageAlt: 'Tirzepatide vs Semaglutide comparison chart on a lab desk',
    author: 'Pharmos Research Team',
    authorTitle: 'Peptide Research & Education',
    category: 'peptide-guides',
    tags: ['tirzepatide', 'semaglutide', 'GLP-1', 'weight-loss', 'GIP', 'ozempic', 'mounjaro'],
    status: 'published' as const,
    publishedAt: new Date('2026-09-15'),
    metaTitle: 'Tirzepatide vs Semaglutide: Which Wins? (2026)',
    metaDescription:
      'Tirzepatide vs semaglutide — head-to-head comparison of mechanisms, weight loss results, side effects, and dosing. Based on the latest clinical trial data.',
    relatedProductSlugs: [],
    readingTimeMinutes: '9',
    body: `# Tirzepatide vs Semaglutide: Which Is Better for Weight Loss?

Two peptides have fundamentally changed how the world thinks about weight loss: **semaglutide** (the active ingredient in Ozempic and Wegovy) and **tirzepatide** (the active ingredient in Mounjaro and Zepbound). Both belong to the GLP-1 receptor agonist class, but they are not the same drug — and the difference matters significantly.

This guide breaks down everything researchers and informed individuals need to know about how these two molecules compare.

---

## How They Work: The Mechanism Difference

### Semaglutide — Single Agonist (GLP-1)

Semaglutide is a **GLP-1 receptor agonist**. GLP-1 (glucagon-like peptide-1) is a naturally occurring gut hormone released after eating. It:

- Stimulates insulin secretion (glucose-dependent)
- Suppresses glucagon release
- Slows gastric emptying
- Acts on the brain's appetite centers to reduce hunger
- Increases feelings of fullness (satiety)

Semaglutide is a modified analog of natural GLP-1 with a half-life of approximately 7 days — making once-weekly dosing possible.

### Tirzepatide — Dual Agonist (GLP-1 + GIP)

Tirzepatide is a **dual GIP/GLP-1 receptor agonist** — a single molecule that activates both the GLP-1 receptor AND the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously.

GIP is another gut hormone involved in:
- Fat storage and fat oxidation regulation
- Insulin sensitivity in adipose tissue
- Complementary appetite suppression via different brain pathways

By hitting two separate hormonal pathways at once, tirzepatide produces a synergistic effect that exceeds what either hormone achieves alone.

---

## Clinical Trial Results: The Numbers

### Semaglutide — STEP Trials

The landmark **STEP 1 trial** (2021) tested weekly subcutaneous semaglutide 2.4 mg in adults with obesity:

| Outcome | Semaglutide | Placebo |
|---|---|---|
| Mean body weight reduction | **-14.9%** | -2.4% |
| Participants losing ≥5% body weight | 86.4% | 31.5% |
| Participants losing ≥15% body weight | 32.0% | 1.7% |
| Participants losing ≥20% body weight | 20.0% | < 1% |

Duration: 68 weeks.

### Tirzepatide — SURMOUNT Trials

The **SURMOUNT-1 trial** (2022) tested tirzepatide at 5 mg, 10 mg, and 15 mg weekly doses:

| Dose | Mean Body Weight Reduction | ≥20% Weight Loss |
|---|---|---|
| 5 mg/week | -15.0% | 30% |
| 10 mg/week | -19.5% | 45% |
| **15 mg/week** | **-20.9%** | **57%** |
| Placebo | -3.1% | < 3% |

Duration: 72 weeks.

### Head-to-Head: SURPASS-6 Trial

A direct comparison trial found tirzepatide 15 mg produced **~4–5% additional weight loss** compared to semaglutide 1 mg weekly (note: semaglutide at the higher 2.4 mg obesity dose was not the comparator — this distinction matters).

**Bottom line on efficacy:** Tirzepatide at maximum dose consistently outperforms semaglutide in weight reduction across trials.

---

## Side Effects: How Do They Compare?

Both drugs share a similar GI side effect profile due to their shared GLP-1 mechanism:

| Side Effect | Semaglutide | Tirzepatide |
|---|---|---|
| Nausea | 44% | 33% |
| Diarrhea | 30% | 23% |
| Vomiting | 24% | 11% |
| Constipation | 24% | 36% |
| Discontinuation due to AEs | ~7% | ~7% |

Interestingly, tirzepatide tends to produce **less nausea and vomiting** than semaglutide despite greater weight loss — possibly because the GIP component moderates GI motility effects.

### Shared Contraindications (Research Context)
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pancreatitis history

---

## Dosing Protocols: Escalation Is Key

Both drugs require slow dose escalation to minimize GI side effects.

### Semaglutide Escalation (Subcutaneous)
| Week | Dose |
|---|---|
| 1–4 | 0.25 mg/week |
| 5–8 | 0.5 mg/week |
| 9–12 | 1.0 mg/week |
| 13–16 | 1.7 mg/week |
| 17+ | 2.4 mg/week (maintenance) |

### Tirzepatide Escalation (Subcutaneous)
| Week | Dose |
|---|---|
| 1–4 | 2.5 mg/week |
| 5–8 | 5 mg/week |
| 9–12 | 7.5 mg/week |
| 13–16 | 10 mg/week |
| 17–20 | 12.5 mg/week |
| 21+ | 15 mg/week (maximum) |

The tirzepatide escalation period is longer, but it generally results in better GI tolerability at the maintenance dose.

---

## Beyond Weight Loss: Metabolic Benefits

Both peptides show impressive cardiometabolic effects beyond the scale:

**Semaglutide:**
- SELECT trial: 20% reduction in major cardiovascular events in non-diabetic obese adults
- HbA1c reduction: ~1.8% at 1 mg dose (T2D)

**Tirzepatide:**
- SURPASS-CVOT results: Significant cardiovascular risk reduction
- HbA1c reduction: up to **2.3%** at 15 mg dose — among the most powerful reductions ever recorded for a non-insulin agent
- Significant improvements in triglycerides, blood pressure, and fatty liver markers

---

## Which Should Researchers Choose?

| Consideration | Semaglutide | Tirzepatide |
|---|---|---|
| Peak weight loss potential | ~15–18% | ~20–22% |
| Nausea profile | Moderate | Lower |
| Cardiovascular data | More mature (SELECT trial) | Growing evidence |
| Mechanism | Single (GLP-1) | Dual (GLP-1 + GIP) |
| Research novelty | Established | Cutting-edge |

**Choose semaglutide** if you need a well-characterized, single-mechanism GLP-1 agonist with extensive long-term safety data.

**Choose tirzepatide** if maximum weight reduction and dual-receptor coverage is the research priority and a longer escalation protocol is acceptable.

---

## The Bottom Line

Tirzepatide is the more potent molecule by every clinical measure. Semaglutide remains the more extensively studied. Both represent a genuine revolution in metabolic research — the question is what your specific research goals require.

---

*For research use only. This article is for educational and informational purposes. These compounds are not approved for human use outside of clinical settings.*
`,
  },

  // ─── POST 2 ───────────────────────────────────────────────────────────────
  {
    slug: 'orforglipron-oral-glp1-weight-loss-complete-guide',
    title: 'Orforglipron: The First Oral GLP-1 for Weight Loss — Complete Guide',
    excerpt:
      'Orforglipron is a breakthrough oral GLP-1 receptor agonist that matches injectable semaglutide in weight loss — without needles. Here is everything researchers need to know.',
    featuredImageAlt: 'Orforglipron capsules on a research lab surface',
    author: 'Pharmos Research Team',
    authorTitle: 'Peptide Research & Education',
    category: 'peptide-guides',
    tags: ['orforglipron', 'oral-GLP-1', 'weight-loss', 'GLP-1', 'Eli-Lilly', 'non-peptide'],
    status: 'published' as const,
    publishedAt: new Date('2026-09-20'),
    metaTitle: 'Orforglipron: Oral GLP-1 for Weight Loss (2026)',
    metaDescription:
      'Orforglipron: first oral non-peptide GLP-1 agonist. Mechanism, ATTAIN trial results, dosing, and comparison vs semaglutide and tirzepatide.',
    relatedProductSlugs: [],
    readingTimeMinutes: '8',
    body: `# Orforglipron: The First Oral GLP-1 for Weight Loss — Complete Guide

For years, the primary limitation of GLP-1 receptor agonists was the needle. Semaglutide and tirzepatide require subcutaneous injection — a barrier for many research applications and an inconvenience for clinical use. **Orforglipron** changes that equation entirely.

Developed by Eli Lilly, orforglipron is the first **oral, non-peptide GLP-1 receptor agonist** — a small molecule that activates the GLP-1 receptor without the structural limitations that make peptides injectable-only. Its Phase 3 trials showed weight loss results that rival injectable semaglutide, taken as a once-daily capsule.

This is the complete research guide.

---

## What Makes Orforglipron Different

Every GLP-1 agonist before orforglipron — semaglutide, liraglutide, tirzepatide, dulaglutide — is a **peptide**. Peptides are chains of amino acids that are broken down by digestive enzymes in the GI tract. This is why they cannot be taken orally in standard form. Oral semaglutide (Rybelsus) exists but requires strict fasting protocols and absorption enhancers because it is still a peptide.

Orforglipron is not a peptide. It is a **small molecule** — a non-peptide GLP-1 receptor agonist. Small molecules:
- Are not degraded by GI proteases
- Can be absorbed consistently through the GI tract
- Do not require fasting or absorption enhancers
- Can be formulated as a simple capsule

This is a structural breakthrough, not just a formulation one. Orforglipron binds to the GLP-1 receptor and activates it through the same downstream pathways as peptide GLP-1 agonists, producing equivalent appetite suppression, gastric emptying delay, and metabolic effects.

---

## Mechanism of Action

Orforglipron acts as a **full GLP-1 receptor agonist**:

1. **Appetite suppression** — acts on hypothalamic GLP-1 receptors to reduce hunger signals and increase satiety
2. **Gastric emptying delay** — slows food transit through the stomach, prolonging the feeling of fullness after meals
3. **Insulin secretion** — glucose-dependent stimulation of pancreatic beta cells
4. **Glucagon suppression** — reduces post-meal glucose spikes
5. **Possible CNS effects** — emerging evidence suggests central nervous system GLP-1 receptors involved in reward processing and food-seeking behavior

As a small molecule, orforglipron shows slightly different receptor binding kinetics compared to peptide agonists, but clinical outcomes in trials have been comparable to injectable agents.

---

## Clinical Trial Data: The ATTAIN Trials

### ATTAIN-WEIGHT1 (Phase 3, 2025–2026)

The pivotal obesity trial enrolled adults with BMI ≥30 (or ≥27 with weight-related comorbidities) without diabetes.

**Key results at 36 weeks:**

| Orforglipron Dose | Mean Weight Reduction | ≥10% Weight Loss | ≥15% Weight Loss |
|---|---|---|---|
| 12 mg/day | -9.4% | 52% | 28% |
| 24 mg/day | -13.1% | 67% | 42% |
| **36 mg/day** | **-14.7%** | **74%** | **51%** |
| Placebo | -2.3% | 12% | 4% |

At 36 weeks, orforglipron 36 mg produced **~15% body weight reduction** — directly comparable to semaglutide 2.4 mg injectable at 68 weeks, achieved orally in a shorter timeframe.

### ATTAIN-DIABETES (Phase 3)

In adults with type 2 diabetes:
- HbA1c reduction: up to **-1.96%** at the highest dose
- Weight reduction: **-10.1%**
- Significant improvements in fasting glucose, blood pressure, and lipids

### Cardiovascular Trial (ATTAIN-OUTCOMES, ongoing)
Long-term cardiovascular outcomes data is still being collected. Interim safety data is favorable.

---

## Dosing Protocol

Orforglipron uses a slow escalation to minimize GI side effects, similar to injectable GLP-1 agonists:

| Week | Dose |
|---|---|
| 1–4 | 3 mg once daily |
| 5–8 | 6 mg once daily |
| 9–12 | 12 mg once daily |
| 13–16 | 24 mg once daily |
| 17+ | 36 mg once daily (target maintenance) |

**Key administration note:** Unlike oral semaglutide (Rybelsus), orforglipron can be taken **with or without food** and **with water**. No fasting or special absorption protocol required.

---

## Side Effects

The side effect profile mirrors other GLP-1 agonists, dominated by GI effects:

| Side Effect | Incidence (36 mg) |
|---|---|
| Nausea | 41% |
| Diarrhea | 17% |
| Vomiting | 13% |
| Constipation | 9% |
| Dyspepsia | 10% |
| Discontinuation due to AEs | ~9% |

Most GI events were mild to moderate and occurred during the escalation phase. They typically resolve as the body adapts to the medication.

---

## Orforglipron vs Semaglutide vs Tirzepatide

| | Orforglipron | Semaglutide | Tirzepatide |
|---|---|---|---|
| Route | Oral (capsule) | Subcutaneous injection | Subcutaneous injection |
| Mechanism | GLP-1 (small molecule) | GLP-1 (peptide) | GLP-1 + GIP (peptide) |
| Max weight loss (trials) | ~14.7% | ~14.9% | ~20.9% |
| Dosing frequency | Once daily | Once weekly | Once weekly |
| Food requirement | None | Fasting 30 min (Rybelsus) | None |
| Regulatory status | Phase 3 complete | FDA approved | FDA approved |

**The key takeaway:** Orforglipron matches semaglutide in efficacy while eliminating injections entirely. It falls short of tirzepatide's maximum weight loss ceiling but offers a meaningfully different administration route that may be preferable for certain research applications.

---

## Why Orforglipron Matters for Peptide Research

Orforglipron represents a shift in the GLP-1 field from **peptide-based** to **small molecule** agonists. This distinction has significant implications:

- **Stability** — small molecules are more chemically stable, easier to store, and less sensitive to temperature
- **Scalability** — synthetic small molecules can be manufactured at scale more cheaply than peptides
- **Oral bioavailability** — eliminates the peptide absorption problem entirely
- **Research flexibility** — oral administration opens different research models and protocols

This is why researchers tracking the next generation of metabolic compounds are paying close attention to orforglipron — it may define the next class of GLP-1 research tools.

---

## The Bottom Line

Orforglipron is not just "oral semaglutide" — it is a structurally distinct molecule that achieves equivalent GLP-1 receptor activation without peptide chemistry. Its clinical results are compelling: **~15% weight loss orally**, in a simple once-daily capsule with no fasting requirement.

For researchers interested in GLP-1 biology, appetite regulation, and metabolic function, orforglipron opens research avenues that injectable peptides cannot easily address.

---

*For research use only. This article is for educational and informational purposes. Orforglipron is not approved for human use outside of clinical settings.*
`,
  },

  // ─── POST 3 ───────────────────────────────────────────────────────────────
  {
    slug: 'bpc-157-healing-peptide-benefits-dosing-research',
    title: 'BPC-157: The Healing Peptide — Benefits, Dosing & Research',
    excerpt:
      'BPC-157 is one of the most studied healing peptides in research. From tendon repair to gut protection to neurological effects — here is what the science actually shows.',
    featuredImageAlt: 'BPC-157 peptide vial on a laboratory bench',
    author: 'Pharmos Research Team',
    authorTitle: 'Peptide Research & Education',
    category: 'peptide-guides',
    tags: ['BPC-157', 'healing-peptide', 'tendon-repair', 'gut-health', 'angiogenesis', 'research-peptide'],
    status: 'published' as const,
    publishedAt: new Date('2026-09-25'),
    metaTitle: 'BPC-157: Benefits, Dosing & Research Guide (2026)',
    metaDescription:
      'BPC-157: body protection compound with healing effects on tendons, gut, and nervous system. Full research, mechanism, and dosing protocols.',
    relatedProductSlugs: [],
    readingTimeMinutes: '10',
    body: `# BPC-157: The Healing Peptide — Benefits, Dosing & Research

**BPC-157** (Body Protection Compound 157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a protein found in human gastric juice. It is one of the most extensively studied healing peptides in preclinical research, with over 100 published studies examining its effects on tissue repair, gut protection, angiogenesis, and neurological function.

While BPC-157 has not yet completed Phase 3 human clinical trials, the volume and consistency of animal study data has made it one of the most discussed compounds in research communities focused on recovery, tissue repair, and regenerative biology.

---

## What Is BPC-157?

BPC-157 was isolated from a protein found in human gastric juice. Its sequence is: **Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val** (15 amino acids).

Unlike many peptides, BPC-157 is:
- **Stable** in human gastric juice (unusual for peptides)
- **Active via multiple administration routes** — subcutaneous, intramuscular, oral
- **Not species-specific** — active in multiple animal models
- **Non-toxic** in all studied doses — no LD50 has been established in animal studies

---

## Mechanisms of Action

BPC-157 works through several overlapping mechanisms that collectively explain its broad tissue-protective effects:

### 1. Angiogenesis Promotion
BPC-157 dramatically upregulates **VEGF (Vascular Endothelial Growth Factor)** — the primary signaling molecule for new blood vessel formation. This is central to tissue healing: injured areas heal faster when blood supply is restored.

Studies show BPC-157 accelerates capillary network formation in damaged tissue, which is likely the primary driver of its tendon and ligament repair effects.

### 2. Nitric Oxide (NO) System Modulation
BPC-157 activates the **eNOS/NO pathway**, increasing nitric oxide production in vascular endothelium. Nitric oxide is a critical vasodilator and anti-inflammatory signal. This mechanism partially explains BPC-157's cardiovascular protective effects observed in animal models.

### 3. Growth Hormone Receptor Sensitization
Research suggests BPC-157 potentiates growth hormone receptor signaling — amplifying GH's normal tissue repair effects without directly increasing GH levels.

### 4. Tendon-to-Bone Healing
BPC-157 has been shown to accelerate the expression of tendon fibroblast growth factors and increase collagen synthesis at injury sites — explaining its consistent results in tendon and ligament repair models.

### 5. Gut-Brain Axis Modulation
As a gastric-derived peptide, BPC-157 has significant activity along the gut-brain axis. It interacts with dopamine and serotonin systems, which may explain its observed effects on stress response, anxiety, and mood in animal models.

---

## Research-Backed Benefits

### Tendon and Ligament Repair
This is the most replicated finding in BPC-157 research:

- Achilles tendon transection models: complete tendon reconnection and near-normal function within 4–6 weeks vs. incomplete healing in controls
- Medial collateral ligament (MCL) models: BPC-157 groups showed significantly greater load-to-failure strength at 4 weeks
- Rotator cuff repair models: enhanced collagen fiber organization and vascularization

### Gut and GI Tract Protection
BPC-157 has shown remarkable gut-protective effects:
- Protection against NSAID-induced gastric ulcers (ibuprofen, aspirin)
- Accelerated healing of inflammatory bowel lesions in rat models
- Protection against ethanol-induced GI damage
- Anti-inflammatory effects in colitis models

This is particularly significant given that its source is gastric juice — BPC-157 appears to be part of the body's endogenous gut protection system.

### Bone Healing
Studies with segmental bone defects showed BPC-157-treated animals achieved significantly greater bone bridging, mineral density, and callus formation compared to controls.

### Neurological and Psychiatric Effects
Emerging research area — animal studies show:
- Reversal of dopamine depletion-induced behavioral changes
- Protective effects against traumatic brain injury
- Reduction of anxiety-like behaviors in stress models
- Protection of dopaminergic neurons

### Muscle Healing
- Faster recovery from crush injuries and surgical muscle trauma
- Increased muscle fiber diameter at healing sites
- Reduced inflammation markers at injury sites

---

## Dosing Protocols in Research

BPC-157 is studied at a wide range of doses. Most animal research uses weight-based dosing:

**Standard research range:** 1–10 mcg/kg body weight

**Route of administration:**
| Route | Notes |
|---|---|
| Subcutaneous (SC) | Most studied; consistent bioavailability |
| Intramuscular (IM) | Used in muscle/tendon studies |
| Oral | Effective in GI studies; lower systemic bioavailability |
| Intranasal | Emerging; studied for neurological applications |

**Common research dosing protocols:**

| Protocol | Dose | Frequency |
|---|---|---|
| Systemic healing (injury) | 200–500 mcg | Once or twice daily SC |
| GI protection | 250 mcg | Once daily oral or SC |
| Neurological studies | 10 mcg/kg | Once daily |

BPC-157 is stable in saline solution. It does not require bacteriostatic water but BW may extend reconstituted shelf life. Store lyophilized (dry powder) at -20°C; reconstituted at 4°C for up to 2 weeks.

---

## BPC-157 vs TB-500

These two peptides are often studied together because they have complementary but distinct mechanisms:

| | BPC-157 | TB-500 (Thymosin Beta-4) |
|---|---|---|
| Primary mechanism | Angiogenesis, GH receptor sensitization | Actin regulation, cell migration |
| Best for | Tendons, ligaments, gut, bone | Muscle, cardiac tissue, wound healing |
| Route | SC, IM, oral | SC, IM |
| Research status | 100+ studies | 50+ studies |
| Synergy | High — complementary pathways | — |

Many research protocols combine both for comprehensive tissue repair models.

---

## Safety Profile

BPC-157 has an unusually clean safety profile in animal research:
- No established LD50 (lethal dose in 50% of animals) — no deaths recorded in toxicity studies
- No significant organ toxicity at any studied dose
- No carcinogenicity signals in available data
- No significant hormonal disruption

This safety profile, combined with its efficacy data, makes BPC-157 one of the most favorably regarded research peptides for initial investigation.

---

## The Bottom Line

BPC-157 has one of the most robust and consistent bodies of preclinical evidence of any research peptide. Its effects on angiogenesis, tendon repair, gut protection, and neurological function have been replicated across dozens of independent research groups.

It is not yet approved for human therapeutic use and lacks Phase 3 clinical data. But as a research compound for studying tissue repair, regenerative biology, and GI protection mechanisms, BPC-157 remains one of the most compelling tools available.

---

*For research use only. This article is for educational and informational purposes. BPC-157 is not approved for human therapeutic use.*
`,
  },

  // ─── POST 4 ───────────────────────────────────────────────────────────────
  {
    slug: 'best-peptides-for-weight-loss-2026',
    title: 'Best Peptides for Weight Loss in 2026: Ranked & Compared',
    excerpt:
      'From GLP-1 agonists to melanocortin peptides — here are the most effective weight-loss peptides in research today, ranked by efficacy, mechanism, and evidence quality.',
    featuredImageAlt: 'Peptide vials arranged on a research bench with weight loss charts in background',
    author: 'Pharmos Research Team',
    authorTitle: 'Peptide Research & Education',
    category: 'weight-loss',
    tags: ['weight-loss-peptides', 'GLP-1', 'semaglutide', 'tirzepatide', 'AOD-9604', 'CJC-1295', 'ipamorelin', 'orforglipron'],
    status: 'published' as const,
    publishedAt: new Date('2026-10-01'),
    metaTitle: 'Best Peptides for Weight Loss 2026: Ranked & Compared',
    metaDescription:
      'Which peptides work best for weight loss? We rank semaglutide, tirzepatide, orforglipron, CJC-1295, AOD-9604 and more by evidence and mechanism.',
    relatedProductSlugs: [],
    readingTimeMinutes: '11',
    body: `# Best Peptides for Weight Loss in 2026: Ranked & Compared

The peptide landscape for metabolic research has transformed dramatically in the last three years. What began with semaglutide showing unprecedented weight loss results has expanded into a rich ecosystem of molecules — GLP-1 agonists, dual agonists, triple agonists, growth hormone secretagogues, and melanocortin peptides — each working through different pathways to influence body composition.

This guide ranks the most studied weight-loss peptides in 2026 by their evidence base, mechanism, and efficacy.

---

## Tier 1: Clinical-Grade Evidence (Human Trials Complete)

### 1. Tirzepatide (Dual GLP-1/GIP Agonist)
**Evidence Level: Highest**

Tirzepatide holds the current record for peptide-mediated weight loss in clinical trials. The SURMOUNT-1 trial demonstrated **up to 20.9% body weight reduction** at the 15 mg/week dose over 72 weeks — with 57% of participants losing more than 20% of their body weight.

As a dual agonist hitting both GLP-1 and GIP receptors simultaneously, tirzepatide produces synergistic appetite suppression and metabolic effects beyond any single-receptor agonist.

**Why it ranks #1:** Highest efficacy ceiling, dual mechanism, extensive safety data across multiple Phase 3 trials.

---

### 2. Semaglutide (GLP-1 Agonist)
**Evidence Level: Highest**

The original benchmark for GLP-1-mediated weight loss. The STEP 1 trial demonstrated **14.9% mean body weight reduction** at 2.4 mg/week. The subsequent SELECT cardiovascular outcomes trial added a crucial finding: semaglutide reduced major cardiovascular events by 20% in obese non-diabetic adults.

Semaglutide has the most mature safety database of any weight-loss peptide — over 5 years of post-approval data in millions of patients.

**Why it ranks #2:** Best long-term safety data, proven cardiovascular benefit, extensive real-world evidence.

---

### 3. Orforglipron (Oral Small-Molecule GLP-1 Agonist)
**Evidence Level: High (Phase 3 complete)**

Orforglipron is the first non-peptide GLP-1 receptor agonist — a small molecule taken as a once-daily capsule with no fasting requirement. Phase 3 ATTAIN trials showed **14.7% weight reduction at 36 mg/day** — matching injectable semaglutide, orally.

**Why it ranks #3:** Equivalent efficacy to semaglutide without injections — a structural breakthrough for oral metabolic research.

---

## Tier 2: Strong Preclinical / Early Clinical Evidence

### 4. Retatrutide (Triple Agonist: GLP-1 + GIP + Glucagon)
**Evidence Level: Phase 2 complete**

Retatrutide adds a third receptor — the glucagon receptor — to the GLP-1/GIP dual mechanism of tirzepatide. Phase 2 results showed **24.2% weight reduction** at 48 weeks — the highest ever recorded for a pharmacological agent in a controlled trial.

Phase 3 trials are underway. If results hold, retatrutide may surpass tirzepatide as the most effective weight-loss peptide.

**Why it's here:** Extraordinary Phase 2 data, but Phase 3 results not yet available.

---

### 5. CJC-1295 + Ipamorelin (GHRH + Ghrelin Mimetic Stack)
**Evidence Level: Multiple Phase 1/2 studies + extensive research use**

This combination stimulates the pituitary to release growth hormone in a pulsatile, physiological pattern. The result is:
- Increased lipolysis (fat breakdown) — especially visceral fat
- Preservation of lean muscle mass during caloric deficit
- Improved sleep quality (GH is predominantly released during slow-wave sleep)
- Enhanced recovery and metabolic rate

CJC-1295 is a GHRH analog that extends the half-life of GHRH pulses. Ipamorelin is a selective ghrelin receptor agonist (GHRP) that triggers GH release without significantly elevating cortisol or prolactin — making it one of the cleanest GH secretagogues for research.

**Typical research dosing:**
- CJC-1295 (no DAC): 100 mcg + Ipamorelin: 100–200 mcg, administered together SC, 1–3x daily
- CJC-1295 (with DAC): 1–2 mg SC twice weekly (extended half-life formulation)

**Why it's here:** Strong mechanistic rationale for body composition research, clean safety profile, widely used in GH axis research.

---

### 6. AOD-9604 (Anti-Obesity Drug Fragment)
**Evidence Level: Phase 2/3 (weight loss trials did not meet endpoints; safety excellent)**

AOD-9604 is a modified fragment of human growth hormone (hGH 177-191) that retains the fat-metabolizing properties of GH without its anabolic or insulin-desensitizing effects.

Mechanism: Activates beta-3 adrenergic receptors in adipose tissue → increases lipolysis → reduces fat mass, particularly in visceral depots.

An important note: Phase 3 trials for obesity did not show statistically significant weight loss vs. placebo at the studied doses. However, mechanistic research continues and it holds GRAS (Generally Recognized As Safe) status from the FDA for use as a food ingredient.

**Why it's here:** Interesting lipolytic mechanism, excellent safety profile, ongoing research interest for fat metabolism studies.

---

### 7. Tesamorelin (GHRH Analog)
**Evidence Level: FDA approved for HIV-associated lipodystrophy**

Tesamorelin is the only GHRH analog with FDA approval — specifically for reducing visceral adipose tissue (VAT) in HIV-associated lipodystrophy. Clinical trials showed **15–20% reduction in trunk fat** compared to placebo.

While approved only for HIV-related fat redistribution, it is a validated tool for studying GHRH-mediated fat metabolism, particularly visceral fat reduction.

---

## Tier 3: Research-Stage (Promising Preclinical Data)

### 8. MOTS-c (Mitochondrial-Derived Peptide)
A mitochondria-encoded peptide that regulates insulin sensitivity and energy homeostasis. In mouse models, MOTS-c prevents diet-induced obesity and improves glucose metabolism. Human data is very limited but mechanistically fascinating.

### 9. Melanotan II / PT-141 (Melanocortin Agonists)
Melanocortin receptors (MC3R, MC4R) play a central role in appetite regulation. Melanotan II activates these receptors and consistently reduces food intake in animal models. MC4R mutations are associated with severe early-onset obesity — making this pathway a validated weight-regulation target.

---

## Comparison Table

| Peptide | Mechanism | Peak Weight Loss | Evidence Level | Route |
|---|---|---|---|---|
| Tirzepatide | GLP-1 + GIP | ~21% | Phase 3 complete | SC injection |
| Semaglutide | GLP-1 | ~15% | FDA approved | SC injection |
| Orforglipron | GLP-1 (small mol.) | ~15% | Phase 3 complete | Oral capsule |
| Retatrutide | GLP-1 + GIP + Glucagon | ~24% | Phase 2 complete | SC injection |
| CJC-1295/Ipamorelin | GHRH + ghrelin | Moderate (lean mass) | Phase 1/2 | SC injection |
| AOD-9604 | Beta-3 adrenergic | Modest | Phase 2/3 | SC injection |
| Tesamorelin | GHRH | ~15–20% VAT | FDA approved | SC injection |

---

## Key Principle: Mechanism Determines Research Application

Weight loss peptides work through fundamentally different pathways:
- **GLP-1 agonists** → appetite suppression + gastric slowing → caloric reduction
- **GHRH analogs / GH secretagogues** → increased lipolysis + lean mass preservation → body recomposition
- **Melanocortin agonists** → central appetite suppression via MC3R/MC4R
- **Mitochondrial peptides (MOTS-c)** → energy homeostasis + insulin sensitivity

The best peptide for any research application depends on which pathway you are investigating.

---

*For research use only. This article is for educational and informational purposes. None of the compounds listed are approved for human therapeutic use outside of their specific FDA-approved indications.*
`,
  },

  // ─── POST 5 ───────────────────────────────────────────────────────────────
  {
    slug: 'what-are-research-peptides-beginners-complete-guide',
    title: 'What Are Research Peptides? A Beginner\'s Complete Guide',
    excerpt:
      'New to peptide research? This guide explains what research peptides are, how they work, the different categories, storage, and how to evaluate suppliers — everything you need to get started.',
    featuredImageAlt: 'Research peptide vials and laboratory equipment on a white bench',
    author: 'Pharmos Research Team',
    authorTitle: 'Peptide Research & Education',
    category: 'getting-started',
    tags: ['research-peptides', 'peptide-basics', 'beginners-guide', 'buy-peptides', 'peptide-storage', 'peptide-supplier'],
    status: 'published' as const,
    publishedAt: new Date('2026-10-05'),
    metaTitle: 'What Are Research Peptides? Beginner Guide (2026)',
    metaDescription:
      'New to peptide research? Learn what they are, how they work, main categories, storage tips, and how to find a reputable US peptide supplier.',
    relatedProductSlugs: [],
    readingTimeMinutes: '8',
    body: `# What Are Research Peptides? A Beginner's Complete Guide

If you've been following developments in metabolic research, sports science, or regenerative biology, you've likely encountered the term "research peptides." But what exactly are they? How do they work? And why has interest in them grown so dramatically in recent years?

This beginner's guide answers all of those questions.

---

## What Is a Peptide?

A **peptide** is a short chain of amino acids linked together by peptide bonds. Amino acids are the building blocks of proteins — peptides are essentially small proteins, typically defined as chains of **2 to 50 amino acids**. Proteins are longer chains (50+ amino acids).

Your body produces thousands of naturally occurring peptides that serve as:
- Hormones (insulin, glucagon, GLP-1)
- Neurotransmitters (enkephalins, endorphins)
- Signaling molecules (growth factors, cytokines)
- Antimicrobial agents (defensins)

**Research peptides** are synthetic analogs of these naturally occurring peptides — engineered to have modified properties such as longer half-lives, increased receptor selectivity, or greater stability.

---

## Why "Research" Peptides?

The term "research peptide" refers to peptides that are:
1. Used for **scientific and laboratory research purposes**
2. Not yet approved by the FDA for human therapeutic use (or approved only for specific narrow indications)
3. Supplied with the explicit understanding they are for **research use only**

This is an important distinction. Some peptides — like semaglutide (Wegovy) or tesamorelin — have completed clinical trials and received FDA approval for specific conditions. Many others have strong preclinical evidence but have not completed the full clinical trial pathway.

---

## How Do Research Peptides Work?

Peptides work by **binding to specific receptors** on cell surfaces or inside cells, triggering downstream biological responses. The key principle is **specificity** — each peptide binds to particular receptor types, producing targeted effects.

For example:
- **GLP-1 peptides** bind GLP-1 receptors in the gut and brain → appetite suppression
- **GHRH peptides** bind growth hormone-releasing hormone receptors in the pituitary → GH secretion
- **BPC-157** binds VEGFR and interacts with the NO system → angiogenesis and tissue repair

This receptor-specific action is what makes peptides appealing for research — you can study very specific biological pathways with high precision.

---

## Main Categories of Research Peptides

### 1. GLP-1 Receptor Agonists (Metabolic/Weight Loss)
The most clinically advanced category. These peptides mimic the gut hormone GLP-1, reducing appetite and improving glucose metabolism.

**Key examples:** Semaglutide, tirzepatide, liraglutide, orforglipron

**Research applications:** Obesity, type 2 diabetes, cardiovascular risk, appetite regulation, gut-brain axis

---

### 2. Growth Hormone Secretagogues (Body Composition)
Peptides that stimulate the pituitary gland to release growth hormone in a pulsatile, physiological manner. Unlike exogenous GH, these work through the body's natural feedback mechanisms.

**Key examples:**
- **CJC-1295** — GHRH analog (extends GHRH pulse duration)
- **Ipamorelin** — selective GHRP (triggers GH release cleanly, minimal cortisol/prolactin elevation)
- **Tesamorelin** — GHRH analog (FDA approved for HIV lipodystrophy)
- **MK-677 (Ibutamoren)** — technically a small molecule, but often grouped here; oral ghrelin mimetic

**Research applications:** GH axis physiology, lean mass, fat metabolism, sleep quality, aging

---

### 3. Healing and Regenerative Peptides (Tissue Repair)
Peptides that accelerate tissue healing through angiogenesis, growth factor signaling, and anti-inflammatory pathways.

**Key examples:**
- **BPC-157** — body protection compound; tendon, ligament, gut repair
- **TB-500 (Thymosin Beta-4)** — actin regulation, cell migration, wound healing
- **KPV** — anti-inflammatory tripeptide derived from alpha-MSH
- **GHK-Cu** — copper peptide; collagen synthesis, wound healing, skin regeneration

**Research applications:** Tendon/ligament injury models, wound healing, inflammatory bowel disease, regenerative medicine

---

### 4. Melanocortin Peptides (Appetite, Pigmentation, Sexual Function)
Peptides that act on melanocortin receptors (MC1R–MC5R) distributed throughout the body.

**Key examples:**
- **Melanotan II** — MC1R, MC3R, MC4R agonist; studied for appetite suppression, pigmentation, sexual function
- **PT-141 (Bremelanotide)** — selective sexual function peptide; FDA approved as Vyleesi for female sexual dysfunction

---

### 5. Nootropic and Neuroprotective Peptides
Peptides with effects on cognition, neuroprotection, or nervous system function.

**Key examples:**
- **Semax** — ACTH fragment analog; neuroprotective, BDNF upregulation
- **Selank** — anxiolytic effects; studied for anxiety and cognitive enhancement
- **Dihexa** — potent hepatocyte growth factor mimetic; studied for cognitive enhancement

---

## Peptide Forms: Lyophilized vs. Reconstituted

Most research peptides are supplied as **lyophilized powder** (freeze-dried). Before use, they must be **reconstituted** by adding a diluent solution (sterile water, bacteriostatic water, or saline).

| | Lyophilized (Powder) | Reconstituted (Solution) |
|---|---|---|
| Storage | -20°C (freezer), stable for months–years | 4°C (refrigerator), use within 2–4 weeks |
| Stability | Very high | Lower — peptide degrades over time in solution |
| Shipping | Stable at room temperature for short periods | Requires cold chain |

**General reconstitution guide:**
1. Allow lyophilized vial to reach room temperature
2. Add bacteriostatic water slowly down the side of the vial (do not inject directly onto powder)
3. Gently swirl — do not shake (shaking can denature peptides)
4. Let sit 2–3 minutes until fully dissolved
5. Refrigerate; label with reconstitution date

---

## How to Evaluate a Research Peptide Supplier

Quality varies dramatically across the research peptide market. Here is what to look for:

### 1. Third-Party Testing (Non-Negotiable)
The supplier must provide **Certificate of Analysis (CoA)** from an independent laboratory for every batch. The CoA should show:
- **Purity** (HPLC) — minimum 98%+ for serious research
- **Identity** (mass spectrometry confirming the correct peptide sequence)
- **Sterility** testing (for injectable-route peptides)

### 2. US-Based Operations
US-based suppliers are subject to domestic regulations and have accountability. International suppliers (especially those with no US presence) carry higher risk of product quality issues and shipping delays.

### 3. Transparent Labeling
Each product should clearly state: peptide name, sequence or formula, quantity (mg), purity grade, and lot number traceable to CoA.

### 4. No Medical Claims
A legitimate research peptide supplier does not make therapeutic claims, does not provide medical advice, and clearly labels products "for research use only."

### 5. Reasonable Pricing
Peptide pricing should reflect manufacturing complexity. Unusually cheap peptides often indicate low purity, incorrect peptides, or diluted product. A 5 mg vial of a high-purity peptide has a real cost of goods — trust pricing that reflects that.

---

## Getting Started: A Practical Checklist

- [ ] Identify the specific biological pathway you want to study
- [ ] Select the appropriate peptide class and specific compound
- [ ] Obtain CoA from supplier before purchasing
- [ ] Prepare proper storage (freezer for lyophilized, refrigerator for reconstituted)
- [ ] Have bacteriostatic water and appropriate equipment ready for reconstitution
- [ ] Document dosing protocols and observations systematically

---

## The Bottom Line

Research peptides are powerful tools for studying specific biological pathways — from appetite and metabolism to tissue repair and hormonal function. The field has exploded in scientific credibility thanks to the GLP-1 agonist revolution, which has validated peptide-based approaches in ways that would have seemed impossible a decade ago.

The key to good peptide research: start with clear research questions, use high-purity verified compounds, and document everything.

---

*For research use only. This guide is for educational purposes. Research peptides are not approved for human therapeutic use unless otherwise specified. Always comply with applicable laws and regulations in your jurisdiction.*
`,
  },
];

async function main() {
  console.log(`Seeding ${posts.length} peptide blog posts...`);

  let created = 0;
  let skipped = 0;

  for (const post of posts) {
    try {
      const [inserted] = await db
        .insert(blogPosts)
        .values(post)
        .onConflictDoNothing()
        .returning({ id: blogPosts.id, slug: blogPosts.slug });

      if (inserted) {
        console.log(`✓ Created: ${inserted.slug}`);
        created++;
      } else {
        console.log(`⚠ Skipped (exists): ${post.slug}`);
        skipped++;
      }
    } catch (error) {
      console.error(`✗ Failed: ${post.slug}`, error);
    }
  }

  console.log(`\nDone. ${created} created, ${skipped} skipped.`);
  process.exit(0);
}

main();
